Loading stock data…
Becton (BDX)
$156.36+3.39 (+2.22%)
Market ClosedLast close Jul 24
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Becton, Dickinson and Company in the Healthcare sector is trading at $156.36 with a market capitalization of $40.1B. Wall Street consensus targets $179.36 (11 analysts), implying a +14.7% move over the next 12 months. The stock is currently 17% below its 52-week high of $187.35, remaining 2.2% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.71B↓ | $5.25B↓ | $5.89B↑ | $5.51B↑ | $4.48B |
| Gross Profit | $2.15B↓ | $2.41B↓ | $2.80B↑ | $2.63B↑ | $1.86B |
| Operating Income | $626.00M↓ | $662.00M↓ | $826.00M↓ | $979.00M↑ | $477.00M |
| Net Income | -$311.00M↓ | $382.00M↓ | $493.00M↓ | $574.00M↑ | $308.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$40.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.25%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.72%
Volume
Today's trading volume
1.11M
Recent News
Reading Between The Lines Of DHR's Latest Call
Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.
Why BSX Stock Hands You So Much Cash Right Now
The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.
Becton, Dickinson and Company Earnings Preview: What to Expect
Becton, Dickinson and Company will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.
How Barron’s Roundtable Panelists’ 2026 Picks Have Performed So Far
The S&P 500 index posted a total return of 9.9% from Jan. 2 through June 30. Here’s how our panelists’ picks did in that period.
The Wide Chasm Priced Into Boston Scientific Stock
If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.